Xencor Inc
No enriched coverage for $XNCR in the last 7 days.
No SEC Form 4 filings for $XNCR in the last 30 days.
See all $XNCR insider activity →Analysts upgraded Xencor, Inc. (NASDAQ:XNCR) revenue forecasts. Consensus revenue for 2026 rose to about $144m from about $77m, implying a 37% increase versus the prior 12 months. The consensus price target stayed at $29.00. The stock gained about 12% to $23.34 over the past week, according to the article.
Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb9
The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.
Recent XNCR coverage spans market movers, earnings and corporate actions.
The article signals a sharp upward revision to Xencor’s revenue outlook, but it notes the consensus price target stayed at $29.
Near-term trading focus is on pipeline execution signals and upcoming readout windows (ESMO 2026 for XmAb819, XENITH-UC interim analysis around year-end 2026, and XmAb412 healthy-participant data in 1H 2027).
The settlement is a tangible cash-flow catalyst that can reduce legal overhang and improve near-term financial visibility.
Settlement converts a previously disputed U.S. royalty stream into near-term cash, reducing uncertainty and improving liquidity visibility through 2028.
The $105 million settlement is a direct cash inflow and removes ongoing U.S. royalty payment uncertainty.
alphai scores every news story that mentions XNCR with an AI model for sentiment and relevance, and aggregates insider trades from Xencor Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts upgraded Xencor, Inc. (NASDAQ:XNCR) revenue forecasts. Consensus revenue for 2026 rose to about $144m from about $77m, implying a 37% increase versus the prior 12 months. The consensus price target stayed at $29.00. The stock gained about 12% to $23.34 over the past week, according to the article.
2 min readXencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb9
7 min readThe following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.
6 min readXencor (NASDAQ:XNCR) said it reached a settlement with Alexion to resolve a U.S. Ultomiris (ravulizumab-cwvz) royalty dispute. Under the agreement, Xencor will receive $105 million in two $52.5 million payments, expected in Aug. 2026 and one year later. Alexion will owe no further U.S. royalties, while ex-U.S. royalties continue. Xencor expects cash through 2028.
4 min readXencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter -- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- -- Ex-U.S. royalties remain unchanged -- PASADENA, Calif.--July 29, 2026-- Xencor, Inc. (
4 min readBiotech stocks hit 52-week highs on July 21, 2026, tied to clinical-trial updates and upcoming earnings. China Pharma Holdings (CPHI) surged over 790% to $19.19. Xencor (XNCR) closed at $21.25, up 8%. Eton Pharmaceuticals (ETON) reached $43.20. 10x Genomics (TXG) closed at $47.20. Acadia Healthcare (ACHC) hit $35.65 intraday.
5 min readBiotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.
4 min readXencor Inc (XNCR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. xncr-20260616 FALSE 0001326732 0001326732 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 8-K ___________________________________________________ CURRENT REPORT Pursuant to Sect
2 min readXencor (NASDAQ: XNCR) reported a significantly wider loss in Q1 2026, with revenue dropping to $4.5 million from $32.7 million year-over-year. This was primarily due to a lack of repeating Incyte milestones, reduced Ultomiris royalty revenue, and a $51.9 million unrealized loss on its equity stake in Zenas BioPharma. The company is also engaged in a royalty dispute with Alexion concerning Ultomiris U.S. payments, leading to a reversal of $6.6 million in previously recorded royalties.
4 min readXencor (XNCR) reported a wider-than-expected Q1 loss of $1.71 per share, significantly missing the Zacks Consensus Estimate of a $0.65 loss, and also lagged revenue estimates with $4.52 million against an expected 75.38% higher figure. Despite beating EPS estimates three times in the last four quarters, the revenue performance was a miss for the quarter ended March 2026. The stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
3 min read